Adagene Inc. (NASDAQ:ADAG – Get Free Report) was the recipient of a large growth in short interest in December. As of December 15th, there was short interest totalling 65,300 shares, a growth of 88.2% from the November 30th total of 34,700 shares. Approximately 0.2% of the company’s stock are short sold. Based on an average daily trading volume, of 60,200 shares, the days-to-cover ratio is currently 1.1 days.
Adagene Stock Performance
Shares of Adagene stock opened at $1.96 on Friday. Adagene has a 12-month low of $1.60 and a 12-month high of $4.38. The business’s 50 day moving average is $2.41 and its 200-day moving average is $2.54.
Hedge Funds Weigh In On Adagene
An institutional investor recently bought a new position in Adagene stock. Mill Creek Capital Advisors LLC acquired a new position in shares of Adagene Inc. (NASDAQ:ADAG – Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 90,908 shares of the company’s stock, valued at approximately $202,000. Mill Creek Capital Advisors LLC owned about 0.21% of Adagene at the end of the most recent reporting period. 9.51% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
View Our Latest Report on ADAG
About Adagene
Adagene Inc, a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors.
See Also
- Five stocks we like better than Adagene
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Power Up: Gaming Industry Expansion Fuels Stock Opportunities
- What Are Dividend Achievers? An Introduction
- These 3 Quirky ETFs May Be Strong Plays in 2025
- What Are Some of the Best Large-Cap Stocks to Buy?
- Buffett Takes the Bait; Berkshire Buys More Oxy in December
Receive News & Ratings for Adagene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adagene and related companies with MarketBeat.com's FREE daily email newsletter.
